Innate Pharma
IPHA
9 hedge funds and large institutions have $255K invested in Innate Pharma in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and closing their positions.
13% more funds holding
Funds holding: 8 → 9 (+1)
0.13% less ownership
Funds ownership: 0.29% → 0.17% (-0.13%)
53% less capital invested
Capital invested by funds: $545K → $255K (-$290K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$883 |
| 2 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$845 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Optiver Holding
Amsterdam,
Netherlands
|
-$163K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$17.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$9.2K |
IPHA Hedge Fund Activity: Q4 2024 in Review
9 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q4 2024, worth a combined $255K — down 53% from $545K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new IPHA positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was RhumbLine Advisers, adding an estimated $883. The largest seller was Optiver Holding, cutting an estimated $163K.
- 9 institutional investors held Innate Pharma (IPHA) as of Q4 2024, up from 8 in Q3 2024.
- Funds reported $255K of Innate Pharma stock for Q4 2024, down 53% quarter-over-quarter.
- 1 fund opened new Innate Pharma positions in Q4 2024 and 0 closed out, a net change of +1 holder.
- The largest Innate Pharma buyer in Q4 2024 was RhumbLine Advisers, an estimated $883 added.
- The largest Innate Pharma seller in Q4 2024 was Optiver Holding, an estimated $163K sold.
Based on aggregated 13F filings for Q4 2024.